Cholangiocarcinoma (CCA) is a rare (incidence rate of less than 6/100,000 in most countries) but extremely deadly malignant tumor. Locally advanced and metastatic CCA cannot be completely removed surgically; current standard treatment options primarily include chemotherapy, radiotherapy, and liver transplantation, with poor prognosis. The 5-year survival rate for intrahepatic CCA is only 9%, and the incidence is even higher in Asian populations.
FGFR fusion mutations are prominent in cholangiocarcinoma. It has been reported that 13%–20% of patients with intrahepatic cholangiocarcinoma carry FGFR2 fusion mutations. These patients are very likely to be sensitive to FGFR inhibitor therapy.
On April 17, 2020, FDA Accelerate approval Incyte Developed by the company FGFR2 inhibitor Pemazyre（pemigatinib） Listed, treatment carried FGFR2 Adult patients with advanced cholangiocarcinoma treated with gene fusion or other rearrangement types. Bringing the first targeted therapy for the treatment of advanced cholangiocarcinoma in adult patients. Pemigatinib Drug Introduction
Drug name: Pemigatinib
Product name: Pemazyre
Manufacturer: Incyte
Specifications: 4.5mg, 9mg, 13.5mg
Hong Kong listing time: January 24, 2022
Reminder: Pemigatinib is the first targeted drug approved in the history of bile duct cancer. Its launch has also made the era of chemotherapy-only chemotherapy for bile duct cancer a thing of the past, giving patients new hope.
